Mirtazapine
In clinical developmentAlso known as 6-Azamianserin, Mepirzapine, Mirataz, Remeron+4 more
6-Azamianserin, Mepirzapine, Mirataz, Remeron, Mirtazapin, Mirtazapina, 1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine, Mirtazapinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Repurposing Mirtazapine in Rett Syndrome: a Multicentric Open Label Phase II Study
Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Archives of general psychiatry1
- Colfax GN1
- Das M1
- Gasper J1
- Matheson T1
- Santos DM1
- Santos GM1
- Shoptaw S1
- Vittinghoff E1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials